Background/Aims: Dipeptidyl peptidase-4 (DPP4) inhibitors are known to have a protective effect on diabetic kidney disease, possibly via reduction of oxidative stress and inflammation in the kidney. However, whether these potential mechanisms play a role in non-diabetic proteinuric kidney diseases is not clear. Methods: Two different animal experiments were carried out using sitagliptin and linagliptin for DPP4 inhibition. In each experiment, male Sprague-Dawley rats were uninephrectomized and randomly divided into vehicle-treated and doxorubicin-treated rats, with or without DPP4 inhibition. Administration of a DPP4 inhibitor was performed daily by oral gavage over six weeks. Results: A single intravenous injection of doxorubicin resulted in hypertension and remarkable proteinuria. Linagliptin, but not sitagliptin, lowered systolic blood pressure in rats with doxorubicin nephropathy. By contrast, sitagliptin ameliorated tubulointerstitial injury, inflammatory cell infiltration, and interstitial fibrosis in rat kidneys with doxorubicin nephropathy. Quantitative polymerase chain reaction analysis revealed that mRNA expression of NLRP3, caspase-1, ASC, and IL-1β was remarkably increased in rat kidneys with doxorubicin nephropathy, and that this upregulation of the major components of the NLRP3 inflammasome was effectively suppressed by treatment with either sitagliptin or linagliptin. Additionally, upregulation of IL-6 was reversed by linagliptin, but not by sitagliptin. On the other hand, sitagliptin, but not linagliptin, reversed the increase in mRNA expression of gp91
Introduction
Dipeptidyl peptidase-4 (DPP4) inhibitors were originally introduced for the treatment of type 2 diabetes mellitus, and their glucose-lowering effect is exerted by increasing the levels of incretin hormones, such as glucagon-like peptide-1 (GLP-1) [1] . In addition to stimulating insulin secretion from pancreatic b cells, DPP4 inhibitors can exhibit pleiotropic action to protect the cardiovascular system, mainly via the type 1 glucagon-like peptide receptor (GLP-1R) [2] . Furthermore, the renoprotective effects of DPP4 inhibition have been demonstrated in diabetic kidney disease models [3] [4] [5] [6] [7] [8] because GLP-1R expression was localized to the vascular smooth muscle cells, glomerular capillaries, and proximal tubule cells in the kidney [9, 10] . Previous in vitro studies have shown that GLP-1 can play a renoprotective role via anti-inflammatory action in mesangial cells [11] and inhibition of angiotensin II in the glomerular endothelium [12] .
The anti-inflammatory action of DPP4 inhibitors has also been explored in non-diabetic animal models, including renal mass reduction [13] , unilateral ureteral obstruction [14] , apolipoprotein E knockout mice [15] , and obesity-induced renal injury [16] . However, the effect of DPP4 inhibitors in non-diabetic 'proteinuric' kidney diseases is not clear. Recently, Higashijima et al. reported that DPP4 inhibitors reduced macrophage infiltration in a rat Thy-1 nephritis model [17] .
In glomerulonephritis, proteinuria determines the progression of renal injury toward interstitial inflammation and fibrosis [18] . It has been recently elucidated that this injury process involves the inflammasome, a complex of cytosolic proteins that typically consists of a sensor (a NOD-like receptor, NLR, or non-NLR), an adapter protein (usually apoptosisassociated speck-like protein containing a caspase activation and recruitment domain, ASC), and caspase-1 [19] . In particular, upregulation of the NLR containing pyrin domain 3 (NLRP3) inflammasome was demonstrated in the setting of proteinuria in cultured proximal tubule cells [20] , podocytes [21] , and a mouse strain with hereditary nephritic syndrome [22] . Here, we extended these investigations to a representative animal model of nephrotic syndrome pathologically characterized by extensive tubular injury, interstitial inflammation, and renal fibrosis [23] . For this, nephropathy was induced by doxorubicin administration, and we tested whether the NLRP3 inflammasome was activated and whether its activation can be ameliorated by DPP4 inhibition in association with changes in renal histopathology and markers of oxidative stress and inflammation.
Materials and Methods

Animal experiments
Pathogen-free, male Sprague-Dawley rats weighing 200-220 g (Orient Bio Inc., Seongnam, Korea) were uninephrectomized and then used in two separate animal experiments for the different DPP4 inhibitors, sitagliptin and linagliptin. In each experiment, the rats were randomly divided into three groups: vehicletreated controls (VCs, n=4 or 5), doxorubicin-treated controls (DCs, n=4 or 5), and doxorubicin/sitagliptincotreated (DS, n=5) or doxorubicin/linagliptin-cotreated (DL, n=5) rats. Doxorubicin (Ildong Pharmaceutical, Seoul, Korea) was administered via the femoral vein as a single bolus (5 mg/kg), and either sitagliptin (10 mg/kg/d; MSD Korea, Seoul, Korea) or linagliptin (3 mg/kg/d; Boehringer Ingelheim Korea, Seoul, Korea) was given by oral gavage once daily for six weeks in cotreated rats. To test whether the DPP4 inhibitors were delivered to the kidney, DPP4 activity was determined from renal tissue homogenates by using a fluorometric assay kit (#K779-100; BioVision, Milpitas, CA, USA). Systolic blood pressure was measured
Renal histopathology
Renal tissue samples were fixed in 4% neutral-buffered formalin and embedded in paraffin. Paraffin sections (4 µm thick) were stained with periodic acid-Schiff reagent (PAS) and Sirius red. Tubulointerstitial injury was scored semiquantitatively on PAS-stained tissues, with a 20x objective. Specifically, tubulointerstitial injury was defined as tubular dilation, tubular atrophy, sloughing of tubular epithelial cells, or thickening of the tubular basement membrane and was scored on a scale of 0 to 4, as follows: 0, no tubulointerstitial injury; 1, <25% of tubulointerstitial injured; 2, 25 to 50% of the tubulointerstitial injured; 3, 51 to 75% of the tubulointerstitial injured; 4, >75% of the tubulointerstitial injured [24] . Areas of tubulointerstitial fibrosis were quantified on Sirius red-stained kidney sections. Ten photographs of randomly selected cortical areas per animal were taken at ×200 magnification using a digital inverted microscope (DMI4000B; Leica Microsystems, Wetzlar, Germany). The photographs were scanned as JPEG files with a resolution of 200 pixels/inch. The total positively-stained area in each image was quantified using Leica Application Suite software (Leica Microsystems).
Immunohistochemistry
Immunohistochemical staining of CD3 and ED1 as markers of T lymphocytes and macrophages, respectively, was performed on formalin-fixed, paraffin-embedded sections using the microwave antigen retrieval method [25] . The primary antibodies were rabbit monoclonal anti-CD3 (Abcam Inc., Cambridge, MA, USA) and mouse monoclonal anti-rat ED1 (Serotec, Oxford, UK). A point-counting technique was used to calculate the number of positively stained interstitial cells in at least 20 consecutive high-power fields [26] .
Quantitative polymerase chain reaction (qPCR) analysis
Total RNA was isolated from the rat whole kidney with TRIzol ® Reagent (Life Technologies, Carlsbad, CA, USA). RNA was quantified by spectrophotometry, and cDNA synthesis was performed using 3 μg of RNA with SuperScript ® III Reverse Transcriptase (Life Technologies). For quantitative polymerase chain reaction (qPCR), 100 ng of cDNA served as a template for PCR amplification using the Brilliant SYBR green QPCR master mix, according to the manufacturer's instructions (FastStart DNA Master SYBR Green I; Roche Molecular Biochemicals, Mannheim, Germany). A serial dilution (1 ng-fg/μL) of cDNA was used as a template to generate a standard curve. Nested primers were used to amplify the standard and kidney cDNA samples ( Table 1 ). The standard and unknown samples were amplified in duplicate in 96-well plates. The thermal profile of the LightCycler ® Instrument (Roche Molecular Biochemicals) was optimized with an initial denaturation for 10 minutes at 95°C and 45 amplification cycles, each consisting of 10 seconds at 95°C, 10 seconds at 60°C, and 10 seconds at 72°C. The comparative Ct method was used to determine the relative amounts of target-mRNA levels, expressed for each sample as a percentage of GAPDH mRNA level. Ct ratios were analyzed using LightCycler ® software (Version 4.05). Specificity was verified by a post-run melting-curve analysis [27] .
ELISA for IL-1β measurement from renal tissue
The concentration of IL-1b from renal tissues was measured using sandwich ELISA [28] . Briefly, monoclonal capture antibody (IL-1β, R&D Systems, Minneapolis, MN, USA) was added to a 96-well plate (Nunc, Roskilde, Denmark) and incubated overnight at 4 °C, following which the plate was washed five times with PBS containing 0.05% Tween-20. Following incubation with blocking solution for 1 hour at room temperature, the test samples and recombinant IL-1β standards were added to the plate. The plate was incubated for 2 hours at room temperature, following which it was washed five times. Biotinconjugated anti-human IL-1β (eBioscience, San Diego, CA, USA) was added and incubated for 1 hour at room temperature; the plate was then washed. Avidin horseradish peroxidase (eBioscience) was then added, with the reaction allowed to proceed for 30 minutes at room temperature. The plate was then washed five times and 3, 3',5, 5'-tetramethylbenzidine solution was added to induce the color reaction, which was attenuated by the addition of 2N H 2 SO 4 . The optical density at 450 nm was measured using an automated microplate reader (VersaMax, Molecular Devices, Palo Alto, CA, USA).
Statistics
Values are presented as means + SD. Differences among the groups were analyzed using the KruskalWallis test. The Mann-Whitney U-test was used for post-hoc comparisons between groups. P-values ≤ 0.05 were considered statistically significant. All statistical analyses were performed using Statview software (Abacus Concepts, Berkeley, CA, USA). 
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Results
Overt nephropathy was induced by a single intravenous injection of doxorubicin in rats with unilateral right nephrectomy, as evidenced by significant elevation of systolic blood pressure (SBP), urinary protein excretion, and elevated plasma creatinine level. Fig. 1 shows that hypertension in doxorubicin nephropathy was significantly controlled by linagliptin but not by sitagliptin treatment. Proteinuria was unaffected by either DPP4 inhibitor (Tables 2 and 3 ). An improving tendency in plasma creatinine and creatinine clearance was observed, but did not reach statistical significance. Table 3 shows that, in response to linagliptin treatment, proteinuria and plasma creatinine level had a decreasing tendency, but did not reach statistical significance. Plasma glucose level was not affected by DPP4 inhibition in either animal experiment. However, DPP4 activity determined from renal tissues was significantly suppressed by daily oral administration of DPP4 inhibitors; When it was compared with doxorubicin-treated controls, both sitagliptin (69 + 19 vs. 100 + 10%, P <0.05) and linagliptin (38 + 2 vs. 100 + 32%, P <0.05) were effective. Fig. 2 shows the results of renal histopathology from the sitagliptin experiment.
A semiquantitative assessment of tubulointerstitial damage in PAS-stained cortical sections revealed that the DS group had a significantly lower tubulointerstitial injury score than the DC group (2.00 ± 0.47 vs. 3.48 ± 0.47 points, P<0.05). The extent of interstitial fibrosis was also lesser in the DS group than in the DC group when estimated by Sirius red staining (19.5 ± 3.6 vs. 27.6 ± 6.1%, P<0.05). Linagliptin treatment produced similar responses in tubulointerstitial injury and interstitial fibrosis (Fig. 3) . Fig. 4 shows the results of immunohistochemical staining of cortical sections for CD3 and ED1. Compared with the DC group, the DS group had significantly fewer interstitial CD3-positive T lymphocytes (45 ± 21 vs. 157 ± 70 cells/HFP, P<0.05) and ED1-positive macrophages (20 ± 6 vs. 31 ± 8 cells/HFP, P<0.05).
Next, we performed a qPCR analysis to investigate the effects of DPP4 inhibition on oxidative stress-related and NLRP3 inflammasome-associated gene expression. As shown in Fig. 5 , mRNA expression of the major components of the NLRP3 inflammasome (NLRP3, caspase-1, and IL-1β) and certain inflammatory cytokines were remarkably upregulated in rat kidneys with doxorubicin nephropathy. Figures 5A and 5B summarize the effects of DDP4 inhibition via the two separate inhibitors. The DS group had significantly lower mRNA levels , and IL-6 (4.0 ± 1.0 vs. 9.7 ± 1.7, P<0.05) than in the DC group. We confirmed that compared with VC (15 ± 3 pg/mg protein), the IL-1b protein concentration determined by ELISA was increased in DC (21 ± 1 pg/mg protein, P<0.05) but was reversed in DL (16 ± 3 pg/mg protein, P<0.05). Fig. 6 shows that doxorubicin-induced nephropathy is accompanied by the upregulation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzymes (NOX1 and NOX2 components) and downregulation of reactive oxygen species neutralizing enzymes, such as superoxide dismutases (CuZn-SOD and Mn-SOD). Compared with the DC group, the DS group had significantly lower mRNA levels of gp91 phox (4.6 ± 0.4 vs. 8.1 ± 0.4, P<0.05), p47 phox (4.2 ± 0.6 vs. 5.6 ± 0.3, P<0.05), and p67 phox (5.3±0.7 vs. 8.1 ± 1.0, P<0.05). However, the decreased mRNA levels of CuZn-SOD and Mn-SOD in doxorubicin nephropathy were not restored by sitagliptin treatment (Fig. 6A) . Interestingly, linagliptin treatment was not successful in blocking the upregulation of oxidative stress-related gene expression in doxorubicin nephropathy (Fig. 6B) . 
Discussion
In this study, we demonstrate that DPP4 inhibitors can suppress NLRP3 inflammasome activation in doxorubicin nephropathy and lead to amelioration of tubulointerstitial injury and interstitial fibrosis. These effects were independent of blood glucose level, and the observed antioxidant effects were inconsistent between sitagliptin and linagliptin.
DPP4 inhibition has been a plausible treatment strategy for management of diabetic nephropathy [29] . However, only a few previous studies have shown that DPP4 inhibitors play a role in preventing the progression of non-diabetic kidney disease. Lee et al. recently reported that DA-1229, a new DPP4 inhibitor, improved proteinuria, renal fibrosis, and inflammation in doxorubicin-treated mice [30] . They suggested a role of DA-1229 in preventing podocyte injury. In non-diabetic rats with 5/6 nephrectomy, linagliptin reduced albuminuria in association with upregulation of downstream targets of atrial natriuretic peptide [31] . Although we failed in reversing heavy proteinuria by using sitagliptin or linagliptin in our rat model of doxorubicin nephropathy, both DPP4 inhibitors were successful in ameliorating tubulointerstitial injury and interstitial fibrosis, most likely via anti-inflammatory action. Previous studies have shown that DPP4 inhibition can improve renal histopathology in animal models of diabetic nephropathy [29, 32] . Among a variety of potential mechanisms by which DPP4 inhibitors exert this renoprotective effect on damaged kidneys, we focused on the regulation of NLRP3 inflammasome activity. Similarly to previous studies [29, 33] , we found no improvement in serum creatinine levels by DPP4 inhibition. Proteinuria contributes to tubulointerstitial inflammation, leading to renal fibrosis. Renal production of inflammatory cytokines is stimulated in rats with heavy proteinuria [34] . Consistent with this, we found that renal mRNA expression of MCP-1 and RANTES was increased in doxorubicin nephropathy. Morphologically, we showed that peritubular infiltration of CD3-and ED1-positive cells was associated with tubulointerstitial injury and renal fibrosis. Finally, we showed that these inflammatory processes were effectively blocked by sitagliptin treatment. Previous studies have shown that sitagliptin treatment reduces renal inflammation and oxidative stress in animal models of type 2 diabetes [29, 35] .
To the best of our knowledge, our results represent the first report demonstrating the activation of the NLRP3 inflammasome in doxorubicin nephropathy. Previous studies have shown that treatment of mice with doxorubicin induced IL-1β release from bone marrowderived macrophages via activation of the NLRP3 inflammasome [36, 37] . Recently, Kobayashi et al. suggested that NLRP3 plays a role in doxorubicin-induced cardiotoxicity [38] . Instead of IL-1β expression, however, it was connected to IL-10 production in macrophages. We found that, in doxorubicin nephropathy, renal mRNA expression of NLRP3, ASC, caspase-1, and IL-1β was remarkably increased. Furthermore, we demonstrated that these effects of NLRP3 inflammasome activation were suppressed by both sitagliptin and linagliptin.
How do DPP4 inhibitors reduce the activity of NLRP3? The role of reactive oxygen species in mediation of NLRP3 activation is the most plausible [39, 40] . Consistent with this, we showed that renal mRNA expression of NOX1 and NOX2 (gp91 phox , p47 phox , and p67 phox ) was increased in doxorubicin nephropathy, and that this upregulation of gp91 phox , p47 phox , and p67 phox mRNA was effectively blocked by sitagliptin treatment. In contrast, the downregulation of NOX4, CuZn-SOD, and Mn-SOD was not altered by DPP4 inhibition. We believe that there exist mechanisms other than antioxidant action by which DPP4 inhibitors suppress the activity of NLRP3, because the effects of linagliptin treatment on the expression of the NLRP3 inflammasome and NOX2 were not parallel.
It is not surprising that the two DPP4 inhibitors, sitagliptin and linagliptin, have different effects on doxorubicin nephropathy. Each of the DPP4 inhibitors might have unique drugspecific effects, because sitagliptin and linagliptin show different activities in their diverse effects on endothelial cell biology [41] . Besides, characteristic pharmacologic actions might be derived from the different binding modes of DPP4 inhibitors in the active site [42] . In this study, linagliptin, but not sitagliptin, had an antihypertensive effect on doxorubicin nephropathy. This discrepancy may be explained by different anti-inflammatory actions between sitagliptin and linagliptin. In our rat kidneys with doxorubicin nephropathy, the upregulation of IL-6 was effectively reversed by linagliptin, but not by sitagliptin. Previous studies using animal models of hypertension have shown that IL-6 may have a role in pathogenesis of hypertension [43, 44] . Furthermore, inhibition of IL-6 was connected to attenuation of associated renal damage [45] [46] [47] . Thus, we believe that antihypertensive effect of linagliptin may be derived from reversing IL-6 upregulation in doxorubicin nephropathy. Besides, the antihypertensive action of linagliptin can be explained by its reported ability to upregulate endothelial nitric oxide synthase (eNOS) and restore endothelium-dependent vasodilation [48, 49] .
Conclusion
We showed that inflammatory processes accompanying NLRP3 inflammasome activation are prominent in doxorubicin nephropathy, and that DPP4 inhibitors can suppress the activity of NLRP3 with or without relieving NOX2-related oxidative stress. Thus, DPP4 inhibitors might be a novel agent to offer anti-inflammatory action in proteinuric kidney disease.
